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might suggest that the original findings1 are false-
positive. However, many of these signals are sup-
ported by previous studies of BP (though sorting out
linkage to psychosis requires more study) or by
studies of schizophrenia, another disorder with major
psychotic features thought to have genes in common
with BP.1,8–10
Our results suggest that for some loci psychotic and
nonpsychotic variants of BP may not be part of the
same genetic ‘spectrum’. This supports our previous
observations1,2 that the presence or absence of
psychosis may be governed by different susceptibility
loci, and that phenotypic dissection of BP may
expedite the search for the underlying genes.
Further study is needed to confirm and extend
these findings.
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Attention-deficit/hyperactivity disorder (ADHD (MIM
143465)) is a common neurobehavioral disorder
characterized by childhood onset and impairment in
multiple settings. ADHD affectsB5% of children and
adolescents and B3% of adults, with a 3–4-fold
prevalence in males1 and similar prevalence rates
observed across diverse populations. Heritability
estimates of 60–90% and reported sibling relative
risks (ls) of B4–8 support a strong genetic etiology.2,3
Currently, three genome-wide linkage studies from
distinct ADHD populations have been published, one
using extended kindreds from a population isolate,4
and two others using affected sibling pair (ASP)
sampling. The University of California at Los Angeles
(UCLA) study5,6 comprises 308 ASPs and parents
recruited from multiple sources in the greater Los
Angeles area.7 The Utrecht University study8 contains
164 ASPs and parents of Dutch, Caucasian ancestry,
recruited from different outpatient clinics in The
Netherlands. Both studies employed the DSM-IV
criteria for diagnoses of ADHD. A third genome scan
in extended kindreds from a population isolate has
been published,4 and comparison to the results of the
joint analysis is discussed further on.
Genome scan analyses and fine mapping investiga-
tions in the UCLA sample support significant linkage
in three regions: 6q12 (MLS 3.30), 16p13 (MLS 3.73),
and 17p11 (MLS 3.63), while the Utrecht two-stage
genome scan supports significant linkage in two
regions: 7p13 (MLS 3.04) and 15q15 (MLS 3.54). Both
studies had lower linkage signals (1 < MLS < 3) at
multiple locations, but only one region of overlap at
5p13 (UCLA MLS = 2.55;6 Utrecht Broad Affection
Criteria MLS = 1.43 and Narrow Criteria MLS = 0.478).
In an attempt to better interpret the lack of replication
across these two data sets, we pooled genotypic data
and re-analyzed the pooled sample in two ways. First,
we estimate linkage evidence across the whole
genome using the pooled sample and empiric
P-values generated by simulations (i.e. generating
empiric P-values based on 1000 replicates per
chromosome using the exact marker information from
the individual scans; for methods, see Ogdie et al.4).
For that analysis, we combined the data into a single
sample and used a single linkage map constructed
from the deCODE high-density map, Marshfield
genetic maps, and the UCSC Genome Browser to
validate the relative order of markers, and performed
multipoint MLS analysis under the possible triangle
(i.e. Holman’s triangle; two-parameter maximization)
using Genehunter v. 2.0. The Utrecht data set
included 434 markers derived mostly from the Weber
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Set 11, and the UCLA data set included 483 markers
derived largely from the ABI Prism Mapping Set v.
2.3. Between the two studies, there were 44 common
markers genotyped in both samples. All markers
common to both studies were globally binned to
ensure consistent allele designation and calculated
allele frequency. Second, we performed an un-
weighted rank-based genome search meta-analysis
(GSMA) of the two genome scans.9,10 The genome was
divided into 120 30-cM bins, the rank orders of all
bins were determined in each sample according to
MLS values, and the probabilities of average rank
(PAR) were calculated. While direct analysis of pooled
genotype data is a more powerful method for detec-
tion of linkage,10 the unweighted GSMA relies
entirely upon the rank order of linkage peaks within
the samples and indicates the likelihood of the
observed overlap between the two studies, indepen-
dent of differing sample sizes and the absolute
magnitude of linkage peaks in a single study.
As the Utrecht sample included ASPs in which one
member had ADHD but the other member could be
ADHD (n = 116) or autistic spectrum disorder (n = 48),
in the pooled analyses the ASPs were restricted to
only the ADHD ASPs (excluding autistic spectrum
disorder), yielding a total collection of 424 ASPs. As
shown in Figure 1, there is evidence for linkage
within each individual study and significant evi-
dence for a risk gene on 5p13 (MLS 3.67, empiric
P = 0.011) based on the pooled data. While the UCLA
data contribute heavily to the joint linkage peak at
5p13, GSMA yields a pointwise significant PAR
(P = 0.049) at that region, indicating a nominally
significant overlap of rank-ordered bins that is
independent of the varying signal strengths in the
two samples (Figure 1c). GSMA defined six bins with
Figure 1 Multipoint MLS and GSMA analysis of the UCLA (a), Utrecht narrow diagnosis (b), and joint data sets (c). The
Y-axis indicates MLS values and X-axis indicates the genetic map of the entire genome (cM). Chromosomes are indicated at
the top of each graph. Graph A (blue) presents the UCLA MLS analysis, graph B (orange) presents the Utrecht analysis, and
graph C (green) presents the joint analysis. Graph C also presents the GSMA PAR as log 10 (p). For (a) and (b), the purple
line indicates the empiric genome-wide threshold for suggestive evidence of linkage (MLS 1.76–1.78) and the red line
indicates the genome-wide threshold for significance (MLS 3.16–3.28). Empiric significance levels were determined by
simulations entailing 1000 replicates of the entire genome for all three data sets. For (c) the purple line indicates the GSMA
threshold for point-wise significance (log 10(0.05)¼ 1.3), and the red line indicates the genome-wide threshold for
significance (MLS 3.19). The joint data set comprises the 116 ASPs under the Utrecht narrow diagnosis and 308 UCLA ASPs.
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PAR < 0.05 (B5p13, 11q25, 13q34,15q26, 16q23, and
20q13; Figure 1c), which is in fact the exact expecta-
tion under the null distribution of two unrelated
linkage scans, suggesting that there are few common
effect loci between the two studies.
In aggregate, both the pooled linkage analysis and
the GSMA indicate that there is a lack of overlap of
linkage peaks with the exception of chromosome
5p13 (Figure 1). In the UCLA sample of 308 ASPs,
when a nominal MLS threshold of 1.0 is used, the
present sample has > 90% power to detect the
susceptibility loci with sibling relative risks (ls)
greater than 1.6. In the Utrecht sample of 164 ASPs,
when an MLS threshold of 1.0 is used, the sample size
provides > 90% power to detect susceptibility loci
with ls > 2.0. Considering that the sharing parameters
underlying the major peaks across both studies (5p,
6q, 7p, 15q, 16p, and 17p11) have an estimated
average lsB1.6, it is unlikely that inadequate sample
size and power can entirely explain the lack of
overlap. Two explanations for the lack of overlap
between studies are (1) heterogeneity of ADHD risk
genes and/or (2) linkage signals within each popula-
tion are false positives.
To evaluate the explanation that individual study
findings reflect false positives, we performed simula-
tions entailing the random splitting of the joint data
set 1000 times into two populations of 308 and 116
ASPs (to match the distribution of LA and Dutch
ASPs with ADHD), followed by multipoint MLS
analysis of the 2000 ‘replicates’. We determined the
local 95% confidence interval (CI; e.g. the MLS
threshold that exceeds 95% of all MLS observed in
the randomly split data sets) across the entire genome
and counted how many times the multipoint MLS
values in the two real data sets exceeded the local
95% CI. Over both samples, there were 17 linkage
peaks exceeding both the nominal level of signifi-
cance (MLS 0.78, empiric P = 0.05) and the local 95%
CI, while only 3–4 peaks were expected under the
null hypothesis (randomly split data), a difference
that is highly significant (P < 4 108). Simply stated,
the linkage signals observed in the individual
samples reflect highly nonrandom excess allele
sharing that cannot be reproduced by randomly
splitting the combined sample into two distinct
populations. These data further support that one or
more of the significant linkage signals within each
sample reflect true linkage and that the lack of
replication between samples is best accounted for by
allele frequency variability at several putative ‘risk’
genes in ADHD.
These results strongly argue that the genetic back-
ground between the Dutch and the Los Angeles
samples are distinct, and suggest that interpopulation
variability in linkage signals may reflect differences
in underlying susceptibility alleles for ADHD. Both
genetic and environmental interacting factors unique
to different populations may affect the penetrance of
causal alleles. Analysis of the allele frequencies of the
44 microsatellites genotyped in both samples further
supports the notion that the two populations have
distinct genetic constituencies. Considering only
alleles with a frequency greater than 1% in at least
one sample, there is an average 1.5-fold difference in
frequency between samples, and 5% of alleles that
exist in both populations exhibit greater than a six-
fold difference in frequency between samples. A
recent genome scan4 in extended ADHD pedigrees
from a Columbian population isolate presents evi-
dence of linkage to 4q13 (LOD 2.4), 5q33 (LOD 1.5),
8q11 (LOD 3.2), 11q22 (LOD 2.4), and a significant
linkage peak overlapping the UCLA data (17p11; LOD
3.90). There are no overlapping regions of linkage
between the Columbian and Utrecht data. Compar-
ison of these three linkage studies in ADHD further
suggests that distinct populations harbor distinct
effect alleles, in addition to common loci presenting
an effect size large enough to be consistently detected
in multiple linkage studies across diverse popula-
tions. By extrapolation, analyses within populations
of similar genetic background are more likely to
generate successful replication for complex traits
such as ADHD, and pooled samples require careful
evaluation of genetic substructures.
The disparate linkage findings between the Utrecht
and UCLA samples may reflect clinical heterogeneity,
as well as population differences in allele frequen-
cies. We minimized clinical heterogeneity between
samples by eliminating Autism/PDD cases from the
Utrecht sample; however, there remained differences
in subtype distributions and socio-economic status
(SES) between the two samples, with the UCLA
sample presenting a greater proportion of inattentive
subtypes and families with high SES rankings. When
the UCLA sample is stratified to match the Utrecht
sample by subtype proportion and SES, there is no
evidence of increased linkage overlap (data not
shown). Other clinical differences may be present
that have yet to be identified (e.g. other co-morbidity
or subclinical variability), precluding our eliminating
clinical heterogeneity as a cause of differences in
linkage signals.
In concert, the evidence presented here highlights
the importance of sharing raw data in collaborations.
By using actual genotype data across both studies, we
were able to demonstrate striking support for between-
sample genetic heterogeneity, within-sample linkage,
and evidence for a common risk gene location (5p13).
Based on these pooled data, the genetic etiology of
ADHD is likely to be influenced by genes of moderate
effect that vary from population to population as a
function of allele frequency variability. Replication of
linkage within populations is likely to be extremely
important for identifying risk genes in ADHD and
collaborations that pool linkage information may
benefit greatly from actual genotype sharing.
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Further evidence of the involvement of alpha-2A-
adrenergic receptor gene (ADRA2A) in inattentive
dimensional scores of attention-deficit/hyperactivity
disorder
Molecular Psychiatry (2006) 11, 8–10.
doi:10.1038/sj.mp.4001743; published online 20 September
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The involvement of alpha-2A-adrenergic receptors
in attention-deficit/hyperactivity disorder (ADHD)
has been early suggested by Arnsten et al.,1
who demonstrated that noradrenergic inputs from
locus coeruleus to prefrontal cortex could improve
cognitive function, through a2 receptors present in
dopamine-containing neurons. Pharmacological
evidences showing that clonidine and guanfacine,
two a2-adrenergic agonists relatively selective for
a2A subtype, are effective in treating ADHD
symptoms2 further suggest that this subtype of
adrenergic receptor can be implicated in ADHD
pathophysiology.
A putative role for alpha-2A-adrenergic receptor gene
(ADRA2A) in ADHD has been initially investigated by
Comings et al.,3 who detected an association of highest
ADHD scores, particularly inattentive scores, with the
homozygosity for the G allele. This was defined by the
presence of an MspI restriction site at position –1291,
created by a C > G single-nucleotide polymorphism
(SNP) (rs 1800544). This association, however, has not
been observed through the Transmission Disequilibrium
Test (TDT) in a subsequent report.4
In our first attempt to investigate the ADRA2A gene
in a Brazilian sample of ADHD patients, the 1291
C > G SNP was analyzed in 92 subjects and their
biological parents.5 Although no association has been
observed through Haplotype Relative Risk method, an
influence of this variation on continuous ADHD
scores was detected: the mean scores at both inatten-
tive and combined (inattentiveþhyperactive/impul-
sive) symptoms were significantly higher in the
probands with the GG (former mm) genotype than in
probands with other genotypes.
A subsequent study from Park et al.6 has given
additional support for an involvement of ADRA2A
gene in ADHD. Here, a sample of 177 nuclear families
was investigated by TDT and Quantitative TDT
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